Industry ownership intelligence

Diagnostics & Research insider conviction

Executive and director activity assessed across 28 companies for breadth, transaction quality, clustering, freshness, and directional conviction.

Market dashboardHealthcare sectorCompany signalsFiling ledgerData API
36/100

Distribution bias

96/100 confidence
Level
Industry
Evidence window
Latest 90 days
Named insiders
184
Latest evidence
11 Sep 2026

Capital positioning read

Distribution bias

Priced common-share disposals are concentrated enough to warrant review, but they are not treated as a standalone bearish forecast.

Demand a stronger confirmation bar

Evidence in favour

  • 119 distinct acquisition events survive duplicate and security-type controls.
  • Participation spans 184 named insiders rather than one filing source.
  • The latest qualifying evidence is fresh, dated 11 Sep 2026.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Conviction36Distribution bias
Confidence96Deep evidence
Controlled events698directional common-share events
Company breadth28represented companies
Acquisition value$94.2Mnormalized amount
Disposal value$995.1Mnormalized amount

Flow regime

Twelve-week filing pressure

Shows the cadence and balance of the full filing tape.

15829 Jun
606 Jul
6313 Jul
2020 Jul
6127 Jul
22903 Aug
6710 Aug
12617 Aug
9324 Aug
6231 Aug
1407 Sep
014 Sep
AcquisitionsDisposalsScore 36 · Confidence 96

Relative positioning

Industry peer map

Current score with confidence.

Drug Manufacturers - GeneralBalanced insider tape5594 confidence Pharmaceutical RetailersNo directional read5014 confidence BiotechnologyBalanced insider tape4893 confidence Medical DevicesBalanced insider tape4792 confidence Medical Instruments & SuppliesDistribution bias4292 confidence Diagnostics & ResearchDistribution bias3696 confidence Drug Manufacturers - Specialty & GenericDistribution bias3495 confidence Medical DistributionDistribution bias3378 confidence Healthcare PlansConcentrated distribution3192 confidence Medical Care FacilitiesConcentrated distribution3187 confidence Health Information ServicesConcentrated distribution2893 confidence

Directional balance

Controlled event mix

17.0%acquisition
Acquisition events
119
Disposal events
579
Net value
-$900.9M

Evidence quality

What the filings represent

Common equity786
Equity compensation66
Options and derivatives105
Other securities2

Decision makers

Role participation

Director346
Other executive287
CEO and chair215
Finance leadership54
Other or unspecified54
Large holder3

Quality controls

Evidence usability

Normalized values
75%
Priced common share
73%
Named insiders
184
Controlled events
698

Auditable evidence

Latest Diagnostics & Research filings

Showing 31 to 60 of 959.

ILMNIllumina Inc
MEISTER, KEITH A.Director
DisposalCommon equity
$2.9MDirectional evidence
ILMNIllumina Inc
MEISTER, KEITH A.Director
DisposalCommon equity
$2.2MDirectional evidence
ILMNIllumina Inc
MEISTER, KEITH A.Director
DisposalCommon equity
$2.1MDirectional evidence
ILMNIllumina Inc
MEISTER, KEITH A.Director
DisposalCommon equity
$1.8MDirectional evidence
ILMNIllumina Inc
MEISTER, KEITH A.Director
DisposalCommon equity
$1.5MDirectional evidence
MYGNMyriad Genetics Inc
FOX, JENNIFER LYNNEChief Legal Officer
DisposalCommon equity
$14.2KDirectional evidence
ILMNIllumina Inc
MEISTER, KEITH A.Director
DisposalCommon equity
$12.3MDirectional evidence
NTRANatera Inc
MOSHKEVICH, SOLOMONPRESIDENT, CLINICALDIAGNOSTICS
DisposalCommon equity
$5.0MDirectional evidence
ILMNIllumina Inc
MEISTER, KEITH A.Director
DisposalCommon equity
$2.3MDirectional evidence
IQVIQVIA Holdings Inc
BERKSHIRE, JAMES G.See Remarks
DisposalCommon equity
$709.6KDirectional evidence
IQVIQVIA Holdings Inc
BERKSHIRE, JAMES G.See Remarks
DisposalOther securities
$709.3KContext evidence
IQVIQVIA Holdings Inc
BERKSHIRE, JAMES G.See Remarks
AcquisitionCommon equity
$709.3KDirectional evidence
IQVIQVIA Holdings Inc
BERKSHIRE, JAMES G.See Remarks
DisposalCommon equity
$697.2KDirectional evidence
VCYTVeracyte Inc
STAPLEY, MARCDirector, Chief Executive Officer
DisposalCommon equity
$394.1KDirectional evidence
VCYTVeracyte Inc
LEITE, JOHNGlobal Chief Commercial Off
DisposalCommon equity
$177.8KDirectional evidence
VCYTVeracyte Inc
FEBBO, PHILLIP G.Chief Scientific & Med Officer
DisposalCommon equity
$163.3KDirectional evidence
VCYTVeracyte Inc
CHAMBERS, REBECCAChief Financial Officer
DisposalCommon equity
$161.7KDirectional evidence
VCYTVeracyte Inc
MCGUIRE, ANNIEEVP, General Counsel
DisposalCommon equity
$144.3KDirectional evidence
VCYTVeracyte Inc
WYGANT, JONATHANVP, Chief Accounting Officer
DisposalCommon equity
$61.1KDirectional evidence
FLGTFulgent Genetics Inc
XIE, JIANPresident and COO
DisposalCommon equity
$41.8KDirectional evidence
FLGTFulgent Genetics Inc
GAO, HANLINChief Scientific Officer
DisposalCommon equity
$32.9KDirectional evidence
CSTLCastle Biosciences Inc
OELSCHLAGER, KRISTEN MChief Operating Officer
DisposalOptions and derivatives
Not reportedContext evidence
LHLaboratory Corporation of America Holdings
CAVENEY, BRIAN JEVP, Pres of BLS, CMO & CSO
AcquisitionEquity compensation
Not reportedContext evidence
LHLaboratory Corporation of America Holdings
MELTZER, JONATHAN CEVP, COO
AcquisitionEquity compensation
Not reportedContext evidence
LHLaboratory Corporation of America Holdings
OYEGUNWA, AKINBOLADEEVP, CIO & CTO
AcquisitionEquity compensation
Not reportedContext evidence
LHLaboratory Corporation of America Holdings
VAUGHN, BRYAN TEVP and President, Diagnostics
AcquisitionEquity compensation
Not reportedContext evidence
NEONeoGenomics Inc
OLIVO, ALICIA CEVP, GC & Business Development
DisposalCommon equity
Not reportedContext evidence
DGXQuest Diagnostics Incorporated
DAVIS, J. E.Director, CEO and President
DisposalCommon equity
$2.4MDirectional evidence
NTRANatera Inc
CHAPMAN, STEVEN LEONARDDirector, CEO AND PRESIDENT
DisposalCommon equity
$545.0KDirectional evidence
NTRANatera Inc
MOSHKEVICH, SOLOMONPRESIDENT, CLINICALDIAGNOSTICS
DisposalCommon equity
$449.3KDirectional evidence

Group-level method

Breadth before headline value

Company breadth

A sector or industry score must be supported across companies. One very large filing cannot manufacture broad conviction.

Economic duplicates

Matching company, date, side, security class, share count, and value records are consolidated for the directional calculation.

Evidence hierarchy

Priced common-share activity determines direction. Compensation and derivative records are mapped separately so ownership mechanics remain visible.

Positioning use

The score identifies where insider alignment merits research or where disposal concentration needs review. Price, trend, valuation, and portfolio risk still decide positioning.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context